The Degenerative Dementia test is based on the detection and quantification of up to 7 blood biomarkers that are specifically altered in patients affected by neurodegeneration due to FTD or AD.

The DD test is conceived as a “screening” tool for use in clinical practice. It is performed using clinical chemistry analyzers commonly used in hospitals, allowing rapid and easy identification of patients in the early stages of neurodegeneration.

The DD test is currently in the IVD development phase and is expected to be available as a RUO kit by 3Q of 2021.